F. Marc LaForce

Challenges and Opportunities While Developing a Group A Meningococcal Conjugate Vaccine Within a Product Development Partnership: A Manufacturer's Perspective From the Serum Institute of India

S. Kapre, Muriel Socquet, Prasad S. Kulkarni, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Preparation and characterization of an immunogenic meningococcal group A conjugate vaccine for use in Africa.

C. Frasch, F. Laforce, Jayant Joshi, 2009, Vaccine.

Development of a group A meningococcal conjugate vaccine, MenAfriVacTM

C. Frasch, M. Préziosi, F. Laforce, 2012, Human vaccines & immunotherapeutics.

Cost-Effectiveness of Alternative Uses of Polyvalent Meningococcal Vaccines in Niger: An Agent-Based Transmission Modeling Study

T. Cohen, R. Yaesoubi, C. Zimmer, 2019, Medical decision making : an international journal of the Society for Medical Decision Making.

Introduction and Rollout of a New Group A Meningococcal Conjugate Vaccine (PsA-TT) in African Meningitis Belt Countries, 2010–2014

Ryan T Novak, W. Perea, F. Diomandé, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

The Meningitis Vaccine Project.

M. Préziosi, F. Laforce, S. Viviani, 2007, Vaccine.

The promise of conjugate vaccines for Africa.

M. Kieny, F. Laforce, F. Marc LaForce, 2007, Vaccine.